Federal Court Weighs Disciplinary Action Against DOJ Lawyers Over Hospital Case

A Washington state court upheld the state’s drug pricing transparency law on June 9, 2026, rejecting a legal challenge brought by pharmaceutical manufacturers. The ruling ensures the state can continue requiring drug companies to report and justify significant price increases to the health department, according to court documents.

Pharmaceutical Research and Manufacturers of America (PhRMA) and other industry groups argued that the law violated the U.S. Constitution’s Commerce Clause and compromised corporate trade secrets. The court dismissed these claims, ruling that the state’s interest in controlling healthcare costs and protecting consumers outweighs the industry’s privacy concerns.

Why did pharmaceutical companies challenge the law?

Industry representatives claimed the law forced companies to reveal proprietary pricing strategies and sensitive commercial data. PhRMA argued that requiring the disclosure of “cost-of-production” and “research and development” expenses for specific drugs constitutes an unconstitutional taking of trade secrets, according to the legal filings.

The plaintiffs further alleged that the law placed an undue burden on interstate commerce. They argued that because drug companies operate nationally, complying with a patchwork of different state-level reporting requirements creates an inefficient and costly regulatory environment.

The court rejected these arguments, stating that the reporting requirements are narrowly tailored to address the public health crisis of rising drug costs. The ruling noted that the state has a legitimate government interest in understanding why prices for life-saving medications increase sharply without corresponding improvements in efficacy.

What does the law require from drug manufacturers?

The legislation requires manufacturers to notify the state when the wholesale acquisition cost of a drug increases beyond a specific percentage threshold within a 12-month period. Once a price hike is triggered, companies must submit a detailed justification for the increase.

According to the statute, the required justifications must include:

• Detailed data on research and development costs associated with the drug.
• A description of the drug’s clinical benefit compared to existing alternatives.
• Information regarding the manufacturer’s marketing and advertising expenditures for the product.
• The number of patents currently protecting the drug from generic competition.

Failure to comply with these reporting requirements can result in civil penalties. The law allows the state to levy fines per day for each violation, according to the regulatory framework established by the Washington health department.

How does this ruling compare to other state efforts?

Washington’s legal victory mirrors a growing trend of state-level drug pricing oversight. California and Vermont have implemented similar transparency laws, both of which faced industry pushback. In those instances, courts have generally sided with state governments, citing the “police power” of states to regulate public health and safety.

However, the Washington law is more stringent than some earlier versions in other states. While some jurisdictions only require the reporting of the price increase itself, Washington’s requirement for “justification” data—including R&D spend—represents a deeper intrusion into corporate financials. This specific requirement was the primary point of contention in the PhRMA lawsuit.

Legal analysts suggest this ruling provides a roadmap for other states currently drafting transparency legislation. By successfully defending the “justification” requirement, Washington has established a precedent that R&D costs are not automatically protected as trade secrets when they are used to justify public price hikes.

What happens next for drug pricing in Washington?

The state health department will now proceed with full enforcement of the reporting mandates. Companies that previously paused their filings pending the court’s decision must now bring their records into compliance to avoid fines.

The state intends to make portions of the reported data available to the public, though it will redact specific proprietary information that does not relate to the price justification. This move is intended to give policymakers and healthcare providers more leverage when negotiating drug contracts.

PhRMA has not yet announced whether it will appeal the decision to a higher court. If the ruling stands, it will solidify Washington’s position as one of the most aggressive states in the U.S. regarding pharmaceutical price oversight.